Histiocytic sarcoma - Targeted therapy: Novel therapeutic options? A series of 4 cases

Onkologie

Volumn 35, Issue 7-8, 2012, Pages 447-450

  Schlick, Konstantin ^a   Aigelsreiter, Ariane ^b   Pichler, Martin ^b   Reitter, Sonja ^b   Neumeister, Peter ^b   Hoefler, Gerald ^b   Beham Schmid, Christine ^b   Linkesch, Werner ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Histiocytic sarcoma; Immunohistochemistry; Targeted therapy; Tumor biology

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; THALIDOMIDE; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; HISTIOCYTIC SARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; PANCYTOPENIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HISTIOCYTIC SARCOMA; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864589613     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000340066     Document Type: Article

References (12)

1. Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES: Clonally related histiocytic/ dendritic cell sarcoma and chronic lymphocytic leukemia/ small lymphocytic lymphoma: A study of seven cases. Mod Pathol 2011;24:1421-1432.
2. Shukla N, Kobos R, Renaud T, Teruya-Feldstein J, Price A, McAllister-Lucas L, Steinherz P: Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer 2011; DOI: 10.1002/cncr.26712.
3. Cazin B, Gorin NC, Jouet JP, Laporte JP, Fenaux P, Walter MP, Najman A, Gosselin B, Bauters F: Successful autologous bone marrow transplantation in second remission of malignant histiocytosis. Bone Marrow Transplant 1990;5:431-433.
4. Gergis U, Dax H, Ritchie E, Marcus R, Wissa U, Orazi A: Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: A case report and review of the literature. J Clin Oncol 2011;29:e251-253.
5. Mainardi C, D'Amore ES, Pillon M, Toffolutti T, Rosolen A: A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant. Leuk Lymphoma 2011;52:1367-1371.
6. Swerdlow S: WHO classification of tumors of haematopoetic and lymphatic tissue. Lyon, IARC, 2008:356-357.
7. Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E: Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol 2007;82:932-933.
8. Dalle JH, Leblond P, Decouvelaere A, Yakoub- Agha I, Preudhomme C, Nelken B, Mazingue F: Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for t-all. Leukemia 2003;17:2056-2057.
9. Teo SK: Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 2005;7:E14-19.
10. Soria C, Orradre JL, Garcia-Almagro D, Martinez B, Algara P, Piris MA: True histiocytic lymphoma (monocytic sarcoma). Am J Dermatopathol 1992; 14:511-517.
11. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP: A phase II trial of single agent bevacizumab in patients with relapsed, aggressive nonhodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009;50:728-735.
12. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.